Angelman Syndrome Foundation opener
  • Walk
  • Contact Registry
  • News
  • Blog
DOnate
  • What is Angelman Syndrome
    • Symptoms and Causes
    • Testing and Diagnosis
    • Genetics of AS
    • Photo Gallery
  • For Parents
    • Newly Diagnosed
    • Accomplishments of Individuals
    • Participate in Research Studies
    • Angelman Therapeutics
  • Research
    • ASF Funded Research
    • Call for Proposals
    • Current Research Studies
    • LADDER
    • Research Funding Philosophy
  • Make an Impact
    • ASF Cure Club
    • Ways To Donate
    • Fundraise
    • Committees & Groups
    • Send Encouragement
    • Shop & Support ASF
    • Volunteer Opportunities
  • Clinics
    • Find a Clinic
    • Clinic Patient Survey
    • For Clinicians
    • Jacob Pritzker Fellowship Program
    • FAQs
  • Resources
    • Search by Topic
    • Adult Resources
    • ASF Family Resource Team
    • ASF Family Fund
    • ASF Family Champions
    • Angelman Syndrome A to Z
    • ASF Podcast
    • Behavior Resources
    • Communication Resources
    • Counseling Services
    • Educational Webinars
    • Federal Resources
    • IEP Resources
    • International AS Resources
    • Medical Resources
    • Seizures
    • Sibling Programs
    • State Resources
  • Events
    • ASF Walk
    • Conferences and Symposia
    • Bank of America Chicago Marathon
  • About
    • Contact ASF
    • Contact Registry
    • Our Partners
    • Board of Directors
    • Communication Advisory Committee
    • Financial Transparency
    • History of ASF and Angelman Syndrome
    • Parent Advisory Committee
    • Scientific Advisory Committee
    • Receive Texts & Emails
    • Privacy

articles and announcements

Categories: Mouse Model

January 23, 2020

Epigenetic regulation of Ube3a by a candidate Angelman syndrome drug (UNCilencer1)

$110,000 The ASF Joseph Wagstaff Postdoctoral Research Fellowship was granted to its first recipient.  Dr. King will do his postdoctoral research on a new drug UNCilencer1, which turns on the silenced paternal UBE3A gene in mouse neurons.  UNCilencer1 is a […]

Read more
Dr. Ype Elgersma
January 15, 2020

To what extent are striatal deficits underlying clinical features of Angelman syndrome?

It remains unclear which brain areas (and hence which cellular changes) directly contribute to phenotypes of AS. Knowledge of the critically affected brain areas is important for two reasons: 1) it will help us to identify the most relevant mechanisms […]

Read more
December 22, 2019

Role of the UBE3A Gene Product in Brain Protein Metabolism

$45,547 Dr. Wagstaff was one of the crucial investigators who discovered that UBE3A disruption was the cause of AS. With funds from this and other projects he was able to develop a mouse model for AS and this important development […]

Read more
December 22, 2019

Dissecting the roles of Ube3a in synaptic plasticity by analyzing synaptic function at the single cell level and utilizing ‘Network Analysis Proteomics’ strategy

$56,000 This grant-funded research was to a premier AS researcher who was instrumental in developing a mouse model for AS and who demonstrated that an important enzyme associated with the synapse, CAMKII, was inhibited or partially inactivated in Angelman mice. […]

Read more
December 22, 2019

Testing for Correction of the Angelman Syndrome Phenotype of UBE3A-Maternal-Deficient Mice by UBE3A Transgene

$47,000 This project was continued funding for an important AS investigator to enable his laboratory to work on studies of UBE3A in the mouse model in the hope of developing novel therapeutic initiatives. The experimental approach in this grant was […]

Read more
December 22, 2019

Effects Of Premature Truncation Of The UBE3A Antisense transcript On UBE3A Imprinted Expression

$82,255 This grant continued ASF funding to one of the premier AS scientists, Dr. Joe Wagstaff, and his laboratory. The aim of this project was a bold attempt to create therapeutic effects in the mouse model by genetically engineering a […]

Read more
December 22, 2019

Elucidating The Function Of The E6AP Ligase At Mammalian CNS Synapses

$50,000 Work from this grant was part of several projects funded by ASF in order to learn more about UBE3A and its relationship to the larger, complex system of protein degradation (called the ubiquitin-proteasome pathway) that is important to all […]

Read more
December 22, 2019

Investigation Of The Role Of UBE3A In Synapse Development

$85,000 We know that UBE3A action inside brain cells is extremely complicated but the research of Dr. Greenberg and his lab has greatly helped to dissect and better understand this complexity. Using mouse models and using powerful genetic technologies to […]

Read more
Page 2 of 8«12345...»Last »

Recent Posts

  • GFAS Ukraine and ASF partner to Launch Clinic in Ukraine
  • AngelmanUK and ASF partner to launch clinics in the UK
  • LADDER Database Receives Transformational Dataset from Ovid Therapeutics
  • ASF Partners with Families in UAE to Expand Clinical Network
  • ASF to Host Screening of Caregiver Documentary, Unseen

Browse

  • What is Angelman Syndrome
  • For Parents
  • ASF Funded Research
  • Make an Impact
  • Events
  • About
  • Angelman Resources & Education
  • Contact Registry
  • News
Address Angelman Syndrome Foundation
3015 E. New York Street
Suite A2 #285
Aurora, IL 60504
Phone800.432.6435 Emailinfo@angelman.org

Connect

  • facebook
  • twitter
  • linkedin
  • instagram
  • pinterest
  • rss
  • youtube

The Mission

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.

  • 4-star charity navigator logo
  • Combined Federal Campaign logo
  • Community Congress logo
Copyright © 2023 Angelman Syndrome Foundation. ALL Rights Reserved. | Site design: BRAND INSPIRATION, LLC